Tetrahidrobiopterin ve Kardiyovasküler Hastalıklar
Özet
Tetrahidrobiopterin (BH4), nitrik oksit (NO), tirozin, serotonin ve fenilalanin içeren esansiyel biyomoleküllerin enzimatik dönüşümlerinde rol oynayan endojen bir kofaktördür. Guanozin trifosfattan (GTP) sentezlenen BH4; sinir, bağışıklık, endokrin ve kardiyovasküler sistem fonksiyonları için kritik biyolojik görevler üstlenir. Oksidatif stres durumunda BH4’ün BH2’ye oksitlenmesi veya sentezinin azalması, nitrik oksit sentaz (NOS) enziminin fonksiyonel olarak ayrılmasına (uncoupling) yol açar. Ayrılan NOS, nitrik oksit üretmek yerine reaktif oksijen türleri üreterek nitro-redoks dengesini bozar ve olumsuz kardiyovasküler sonuçlara neden olur. Bu biyokimyasal bozulma; pulmoner hipertansiyon, hipertansiyon, ateroskleroz ve iskemik kalp hastalıkları gibi vasküler disfonksiyonların gelişimini indükler. Pulmoner hipertansiyonda BH4 eksikliği selektif pulmoner patoloji oluştururken, BH4 uygulanması vazodilatasyonu uyararak hastalığın ilerlemesini engeller. Hipertansiyonda BH4-NOS ayrılması vasküler gevşemeyi bozarak periferik direnci ve kan basıncını yükseltir; BH4 takviyesi ise kan basıncını düşürüp dolaşımdaki endotel progenitor hücrelerin tamir kapasitesini artırır. Aterosklerozda azalan NO seviyeleri trombosit yapışması ve düz kas hücresi çoğalmasına katkıda bulunurken, BH4 veya sepiapterin tedavisi endotel disfonksiyonu düzeltir. İskemi ve reperfüzyon hasarında azalan BH4 biyoyararlanımı kardiyak doku kaybına ve enfarktüse sebep olur; BH4 replasmanı NO üretimini artırıp miyokart fonksiyonlarını korur. Sonuç olarak BH4, kardiyovasküler hastalıkların önlenmesinde ve tedavisinde önemli bir terapötik potansiyele sahiptir.
Referanslar
Kim HK and Han J. Tetrahydrobiopterin in energy metabolism and metabolic diseases. Pharmacol Res. 2020;157(104827. 10.1016/j.phrs.2020.104827
Werner ER, Blau N and Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011;438(3):397-414. 10.1042/bj20110293
Duch DS and Smith GK. Biosynthesis and function of tetrahydrobiopterin. The Journal of Nutritional Biochemistry. 1991;2(8):411-423.
Tayeh MA and Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem. 1989;264(33):19654-8.
Kim HK, Ha SH and Han J. Potential therapeutic applications of tetrahydrobiopterin: from inherited hyperphenylalaninemia to mitochondrial diseases. Ann N Y Acad Sci. 2010;1201(177-82. 10.1111/j.1749-6632.2010.05623.x
Kaufman S, Berlow S, Summer GK, et al. . Hyperphenylalaninemia due to a deficiency of biopterin. A variant form of phenylketonuria. N Engl J Med. 1978;299(13):673-9. 10.1056/nejm197809282991301
Doehring A, Antoniades C, Channon KM, et al. . Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk. Mutat Res. 2008;659(3):195-201. 10.1016/j.mrrev.2008.04.007
Bendall JK, Douglas G, McNeill E, et al. . Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal. 2014;20(18):3040-77. 10.1089/ars.2013.5566
Kase H, Hashikabe Y, Uchida K, et al. . Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J Hypertens. 2005;23(7):1375-82. 10.1097/01.hjh.0000173520.13976.7d
Landmesser U, Dikalov S, Price SR, et al. . Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111(8):1201-9. 10.1172/jci14172
Hattori Y, Hattori S, Wang X, et al. . Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27(4):865-70. 10.1161/01.ATV.0000258946.55438.0e
Tiefenbacher CP, Lee CH, Kapitza J, et al. . Sepiapterin reduces postischemic injury in the rat heart. Pflugers Arch. 2003;447(1):1-7. 10.1007/s00424-003-1131-y
Oidor-Chan VH, Hong E, Pérez-Severiano F, et al. . Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model. PPAR Res. 2016;2016(8237264. 10.1155/2016/8237264
Verma S, Maitland A, Weisel RD, et al. . Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg. 2002;123(6):1074-83. 10.1067/mtc.2002.121687
Félétou M and Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291(3):H985-1002. 10.1152/ajpheart.00292.2006
Francis BN, Salameh M, Khamisy-Farah R, et al. . Tetrahydrobiopterin (BH(4) ): Targeting endothelial nitric oxide synthase as a potential therapy for pulmonary hypertension. Cardiovasc Ther. 2018;36(1):10.1111/1755-5922.12312
Alp NJ and Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24(3):413-20. 10.1161/01.ATV.0000110785.96039.f6
Tsikas D, Böhmer A and Flentje M. Tetrahydrobiopterin and endothelial nitric oxide synthase uncoupling. Hypertension. 2012;59(2):e12-e12.
Channon KM. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med. 2004;14(8):323-7. 10.1016/j.tcm.2004.10.003
Nandi M, Leiper J, Arrigoni F, et al. . Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation. Pediatric research. 2006;59(6):767-772.
Khoo JP, Zhao L, Alp NJ, et al. . Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005;111(16):2126-33. 10.1161/01.Cir.0000162470.26840.89
Francis B, Wilkins M and Zhao L. Tetrahydrobiopterin and the regulation of hypoxic pulmonary vasoconstriction. European Respiratory Journal. 2010;36(2):323-330.
Bode VC, McDonald JD, Guenet JL, et al. . hph-1: a mouse mutant with hereditary hyperphenylalaninemia induced by ethylnitrosourea mutagenesis. Genetics. 1988;118(2):299-305.
Wang S, Xu J, Song P, et al. . Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension. 2008;52(3):484-90. 10.1161/hypertensionaha.108.112094
Bai YP, Xiao S, Tang YB, et al. . Shear stress-mediated upregulation of GTP cyclohydrolase/tetrahydrobiopterin pathway ameliorates hypertension-related decline in reendothelialization capacity of endothelial progenitor cells. J Hypertens. 2017;35(4):784-797. 10.1097/hjh.0000000000001216
Duda DG, Fukumura D and Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004;10(4):143-5. 10.1016/j.molmed.2004.02.001
Giannotti G, Doerries C, Mocharla PS, et al. . Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension. 2010;55(6):1389-97. 10.1161/hypertensionaha.109.141614
Ali ZA, Rinze R, Douglas G, et al. . Tetrahydrobiopterin determines vascular remodeling through enhanced endothelial cell survival and regeneration. Circulation. 2013;128(11 Suppl 1):S50-s58. 10.1161/circulationaha.112.000249
Napoli C, de Nigris F, Williams-Ignarro S, et al. . Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006;15(4):265-79. 10.1016/j.niox.2006.03.011
Douglas G, Hale AB, Patel J, et al. . Roles for endothelial cell and macrophage Gch1 and tetrahydrobiopterin in atherosclerosis progression. Cardiovasc Res. 2018;114(10):1385-1399. 10.1093/cvr/cvy078
Alp NJ, McAteer MA, Khoo J, et al. . Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2004;24(3):445-50. 10.1161/01.Atv.0000115637.48689.77
Dumitrescu C, Biondi R, Xia Y, et al. . Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci U S A. 2007;104(38):15081-6. 10.1073/pnas.0702986104
Baumgardt SL, Paterson M, Leucker TM, et al. . Chronic Co-Administration of Sepiapterin and L-Citrulline Ameliorates Diabetic Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury in Obese Type 2 Diabetic Mice. Circ Heart Fail. 2016;9(1):e002424. 10.1161/circheartfailure.115.002424
